SEND Blog

BiotechCROPharmaceuticalPre-ClinicalRegulatory SubmissionRegulatory SubmissionsSENDSEND Advantage ServicesSensible SEND

Skeuo-what now?!

Marc Ellison

SEND sometimes mimics reported data rather than collected data – like a digital camera’s fake shutter sound mimics the real thing – raising the question of whether these “skeuomorphs” belong in our datasets or not.

BiotechCROPharmaceuticalPre-ClinicalRegulatory SubmissionRegulatory SubmissionsSENDSEND Advantage ServicesSensible SEND

Is the world of SEND moving too fast?

Marc Ellison

March 2021 was huge for SEND – with FDA enforcing Technical Rejection Criteria, releasing new guidance, and CDISC publishing updates.

BiotechCROPharmaceuticalPre-ClinicalRegulatory SubmissionRegulatory SubmissionsSENDSEND Advantage ServicesSensible SEND

Supported but not required by FDA – What’s the point?

Marc Ellison

“Supported but not required” isn’t just a status, it’s a warning. Now’s the time to prepare for SENDIG-DART v1.1 before it becomes mandatory.

BiotechCROPharmaceuticalPre-ClinicalRegulatory SubmissionRegulatory SubmissionsSENDSEND Advantage ServicesSensible SEND

DART, SOT & an FRN – Just another week in the world of SEND

Marc Ellison

The FDA’s surprise Federal Register Notice makes SENDIG-DART officially accepted, and required from March 2023. For those of us who’ve championed it, it’s a long-awaited and exciting milestone.

BiotechCentrusCROPharmaceuticalPre-ClinicalRegulatory SubmissionRegulatory SubmissionsSENDSensible SEND

A picture paints a thousand words

Marc Ellison

Standardized SEND data is unlocking the power of visualization, enabling faster, clearer insights and opening the door to a future beyond static PDFs.

BiotechCentrusCROPharmaceuticalPre-ClinicalRegulatory SubmissionRegulatory SubmissionsSENDSensible SEND

Beyond Compliance?

Marc Ellison

While many still struggle with SEND, a few are venturing Beyond Compliance, unlocking insights from standardized data with tools like SEND Explorer and breathing new life into legacy studies.

Stay up to Date

Get expert tips, industry news, and fresh content delivered to your inbox.